Health and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.K

BACKGROUND: To reduce the likelihood of complications in persons with type 2 diabetes, it is critical to control hyperglycaemia. Monotherapy with metformin or insulin secretagogues may fail to sustain control after an initial reduction in glycemic levels. Thus, combining metformin with other agents...

Descripción completa

Detalles Bibliográficos
Autores principales: Ward, Alexandra J, Salas, Maribel, Caro, J Jaime, Owens, David
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC406422/
https://www.ncbi.nlm.nih.gov/pubmed/15086954
http://dx.doi.org/10.1186/1478-7547-2-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC406422/
https://www.ncbi.nlm.nih.gov/pubmed/15086954
http://dx.doi.org/10.1186/1478-7547-2-2

Ejemplares similares